AUTHOR=Majait S. , Vaz F. M. , Kemper E. Marleen , Bootsma A. H. , Groen A. K. , Nieuwdorp M. , Soeters Maarten R. TITLE=Glycodeoxycholic acid as alternative treatment in 3β-hydroxy-Δ5-C27-steroid-oxidoreductase: a case report JOURNAL=Frontiers in Pediatrics VOLUME=12 YEAR=2024 URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2024.1418963 DOI=10.3389/fped.2024.1418963 ISSN=2296-2360 ABSTRACT=Background

3β-hydroxy-Δ5-C27-steroid-oxidoreductase (3β-HSD) deficiency is a bile acid synthesis disorder that leads to the absence of normal primary bile acids and the accumulation of abnormal bile acids. This results in cholestatic jaundice, fat-soluble vitamin deficiency, acholic or fatty stools and failure to thrive. Bile acid supplementation is used to treat 3β-HSD-deficiency and its symptoms.

Methods

This report details the case of a 28-year-old woman diagnosed with 3β-HSD-deficiency, who was treated with glycine-conjugated deoxycholic acid (gDCA).

Results

gDCA treatment successfully restored normal bile acid levels, improved body weight by reducing fat malabsorption, and was well-tolerated with no observed liver problems or side effects.

Conclusions

As a potent FXR ligand, gDCA might exert its action through FXR activation leading to bile acid synthesis regulation.